4D Molecular Therapeutics Eyes Wet AMD Breakthrough with Gene Therapy 4D-150

4D Molecular Therapeutics (FDMT) is positioning its lead gene therapy, 4D-150, as a transformative approach to wet age-related macular degeneration (AMD), a condition affecting over 90% of Medicare patients. The company highlighted its Phase III trials—4FRONT-1 and 4FRONT-2—during the 12th Annual Cantor Fitzgerald Global Healthcare Conference, projecting a first readout for 4FRONT-1 in the second quarter of 2025 and a second readout for 4FRONT-2 in the second half of 2025. The therapy, which expresses aflibercept—a key component of EYLEA (bevacizumab)—aims to achieve non-inferiority to Q8-week EYLEA dosing on best-corrected visual acuity (BCVA) at week 52, while reducing supplemental injections by targeting a broader patient population with fewer treatment burdens. Clinical data from the PRISM trial suggest 4D-150 could reduce injection frequency by up to 80% in treatment-naive patients and mid-70% in those with longer-term disease, contrasting with current bolus therapies like EYLEA HD and VABYSMO, which often require more frequent dosing than their labeled intervals. The company’s commercial strategy emphasizes a lean footprint, targeting 100–150 employees to address a market dominated by 2,500–2,600 retina specialists, who account for 95% of VEGF treatments. Kristian Humer, CFO, emphasized the therapy’s scientific distinction: ‘We’re not just extending durability by a few weeks; we’re changing the paradigm with an always-on, continuous therapy.’ Chris Simms, CCO, underscored the need for payer alignment, noting that 80% of Medicare Advantage respondents prioritize long-term vision preservation, while 93% expressed concerns over patient persistence. The company also plans to announce Phase III initiation for diabetic macular edema (DME) in late September 2024 and holds $458 million in cash as of June 30, 2024, extending its cash runway to mid-2028. With a market capitalization of $764 million and a 104% year-to-date return, FDMT remains a high-growth biotech navigating a competitive space with rivals like AbbVie’s DURAVYU and Roche’s IZERVAY.